Lenvus

Therapeutic Segment:

Tyrosine Kinase Inhibitor

Generic Name:

Lenvatinib

Indication

Capsules
  • 4mg
  • 10mg

Lenvus (Lenvatinib) is indicated:

  • As monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
  • For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
  • In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
  • In combination with pembrolizumab, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
  • In combination with everolimus for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy.
  • In combination with belzutifan, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor.